Loading clinical trials...

Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux. | Clinical Trials | Clareo Health

COMPLETEDPhase 4NCT00555438

Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.

Fondaparinux is an antithrombotic agent having already received a regulatory approval by the European Authorities in venous thromboembolic event prevention after major orthopaedic surgery, as total hi...

Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne•29 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment451

Start dateJun 2007

Last updatedAug 17, 2011

Condition

Major Orthopaedic Surgery and Renal Impairment

Locations shown

GARANGER Thierry

Agen

CHARRET Françoise

Annonay

BONNEMAISON Julie

Bayonne

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 17, 2011Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions